JG

John Glasspool

Biopharmaceutical Leader

Boston, Massachusetts

Overview 

John Glasspool is a seasoned biopharmaceutical leader based in Boston, Massachusetts, with a strong background in market access, clinical development, and pharmaceutical sales. He has held executive roles at notable companies such as Baxalta and Novartis, overseeing commercial operations, market access, and product launches across various therapeutic areas. Glasspool's career highlights include serving as CEO and President of Anthos Therapeutics Inc and holding key leadership positions at Novartis, where he led marketing and commercial operations for key franchises like Cardiovascular & Metabolism and Neuroscience.

Work Experience 

  • Chief Executive Officer

    2024 - Current

  • Member of the Board Emerging Companies Section Governing Board

    2022

  • Venture Partner

    2018

    Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

A biotech venture capital firm.

  • Board Member

    2019

    Relmada (Nasdaq: $RLMD) is a clinical-stage company developing novel therapies for the treatment of CNS diseases.

Relmada Therapeutics is a biotech company addressing diseases of the central nervous system, with a focus on major depressive disorder.

Raised $306,131,110.00 from BioAdvance.

  • Senior Advisor

    2016

    Advisor/Contributor on key initiatives, including financing/reimbursement models, policy recommendations for durable therapies, and Efficacy to Effectiveness (E2E) strategies.

  • CEO and President

    2019 - 2024

    Anthos Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for high-risk cardiovascular patients. The company’s lead program is abelacimab (MAA868), an antibody exhibiting dual inhibition of coagulation Factor XI and its activated form XIa. Early clinical trials indicate abelacimab has the potential to attenuate pathological thrombosis with minimal impact on hemostasis, thereby preventing or treating a variety of thrombotic disorders with lowered bleeding risk. Abelacimab’s anticipated monthly dosing combined with the potential for greater effectiveness and lowered bleeding profile are expected to provide major advantages over existing standards of care and allow greater numbers of people to be treated.

Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases.

Raised $250,000,000.00 from Blackstone Life Sciences and Novartis.

  • Board Member

    2017 - 2023

    DalCor is pioneering precision medicine for cardiovascular disease. The company is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit.

  • Consultant

    2017 - 2018

    Consulting to Roivant on commercial go-to-market activities, including operating, launch, and access plans.

  • EVP, Head of Corporate Strategy and Customer Operations

    2015 - 2017

    Member of Executive Team that led Baxalta through spin-off from Baxter Healthcare and subsequent merger agreement with Shire to form a Top 20 biopharma company. Championed external product development model and led Baxalta Ventures and Vitesse Biologics, along with more traditional business development and licensing and M&A, to create a conduit between innovation and commercialization.

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing.

  • VP, Head of Emerging Therapies and Market Development, Bioscience

    2012 - 2015

    Built oncology franchise from the ground up with three in-licenses agreements and development of an internal commercial team. Architect of commercial infrastructure for $12 billion business built around the changing needs of multiple stakeholders – patients, physicians, providers, payers, and policymakers (P5) – establishing a comprehensive approach to the successful launch of new drugs.

Articles About John

Relevant Websites